NASDAQ:OCRX - (OCRX) Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.79
+0.30 (1.20%)
Get New (OCRX) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OCRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OCRX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for (OCRX) in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $1.79.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in (OCRX). This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/6/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/1/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/18/2017CowenReiterated RatingBuy$11.00Low
i
11/3/2017HC WainwrightDowngradeBuy ➝ Neutral$1.75N/A
i
Rating by E. Arce at HC Wainwright
5/24/2017AegisReiterated RatingBuy$3.00Low
i
5/10/2017HC WainwrightReiterated RatingBuy$4.00High
i
Rating by E. Arce at HC Wainwright
4/17/2017AegisReiterated RatingBuy$3.00High
i
3/16/2017HC WainwrightReiterated RatingBuy$4.00Medium
i
Rating by E. Arce at HC Wainwright
3/11/2017AegisReiterated RatingBuy$3.00N/A
i
3/10/2017HC WainwrightReiterated RatingBuy$4.00N/A
i
Rating by E. Arce at HC Wainwright
1/31/2017HC WainwrightReiterated RatingBuy$10.00 ➝ $4.00N/A
i
Rating by E. Arce at HC Wainwright
1/31/2017AegisReiterated RatingBuy$8.00 ➝ $3.00N/A
i
1/31/2017JMP SecuritiesDowngradeOutperform ➝ Market PerformN/A
i
1/30/2017Stifel NicolausDowngradeBuy ➝ Hold$1.00N/A
i
1/18/2017AegisReiterated RatingBuy$8.00N/A
i
1/8/2017AegisReiterated RatingBuy$8.00N/A
i
12/28/2016HC WainwrightInitiated Coverageinit ➝ Buy$10.00N/A
i
Rating by E. Arce at HC Wainwright
11/3/2016AegisInitiated CoverageBuy$8.00N/A
i
10/24/2016Brean CapitalSet Price TargetBuy$10.00N/A
i
Rating by Difei Yang at Brean Capital
9/22/2016JMP SecuritiesReiterated RatingBuyN/A
i
4/12/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Difei Yang at Brean Capital
3/6/2016CowenReiterated RatingBuy$11.00N/A
i
Rating by Ritu Baral at Cowen Inc
3/6/2016Brean CapitalReiterated RatingBuy$10.00N/A
i
Rating by Difei Yang at Brean Capital
(Data available from 3/1/2016 forward)
(OCRX) logo
Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.
Read More

Today's Range

Now: $1.79
$1.79
$1.79

50 Day Range

MA: N/A

52 Week Range

Now: $1.79
$0.52
$2.95

Volume

N/A

Average Volume

1,105,401 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of (OCRX)?

The following sell-side analysts have issued stock ratings on (OCRX) in the last twelve months:
View the latest analyst ratings for OCRX.

What is the current price target for (OCRX)?

0 Wall Street analysts have set twelve-month price targets for (OCRX) in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for (OCRX) in the next year.
View the latest price targets for OCRX.

What is the current consensus analyst rating for (OCRX)?

(OCRX) currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OCRX.

How do I contact (OCRX)'s investor relations team?

(OCRX)'s physical mailing address is 555 Twin Dolphin Dr Ste 615, REDWOOD CITY, CA 94065-2130, United States. The biopharmaceutical company's listed phone number is +1-650-4750158 and its investor relations email address is [email protected] The official website for (OCRX) is www.ocerainc.com.